Johnson & Johnson and Protagonist Therapeutics announced two Phase 3 successes for their oral IL-23 drug, showcasing the ...

T cell therapy for autoimmune diseases, showing clinical responses in seven lupus patients. The therapy uses the same ...

Efforts by the pharmaceutical industry to expand access to low-and-middle-income countries need to be “vastly accelerated” ...

They've got $70 million, two guys named Ned, and plans to go after early-stage science where other venture capital firms ...

Merck's subcutaneous version of Keytruda succeeded in Phase 3 trials, showing non-inferior results to its IV counterpart. The ...

Synapticure, a startup building digital health tools for people with neurodegenerative conditions and their caregivers, has ...

Therapists can’t be around for their patients 24/7. One startup is betting AI can be the solution. When trained with clinical ...

Biogen and UCB on Tuesday shared an expanded dataset for their Phase 3 lupus program, which they said two months ago ...

Regenxbio reported improved muscle function in boys with Duchenne muscular dystrophy using their gene therapy RGX-202. The ...

Alnylam's nucresiran showed promising results in Phase 1 trial for rare cardiomyopathy, achieving up to 96% TTR reduction at ...

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

New hepatitis D treatment data from Vir Biotechnology and Bluejay Therapeutics shows promising results in reducing viral levels. Both companies plan further trials, with Vir targeting Phase 3 in 2025.